



Contact:

Howard J. Leonhardt
Executive Chairman & CEO
954 401 0096
howard@leonhardtventures.com
www.leonhardtventures.com

Funding: \$11.3mm raised to date

- \$3.1 mm for innovation accelerator
- + \$8.2 mm for portfolio assets
- \$11.9 mm left in current raise

Competitive Advantage:

- + First innovation accelerator focused on organ regeneration.
- + 700+ patent claims issued, pending, optioned or licensed for organ regeneration and recovery.


Management Team:

Howard J. Leonhardt - 30+ patents, serial entrepreneur, invented and developed leading stent graft system.

Dr. Leslie Miller - 250+ published papers, 100+ clinical trial, former Chairman of Cardiovascular Medicine at University of Minnesota, Cardiologist

Intellectual Property:

Leonhardt's Launchpads and its portfolio innovation assets have exclusive rights to over 700 patent and patent pending claims for organ regeneration and recovery.



Overview:

Leonhardt's Launchpads is the world's first innovation accelerator focused on organ regeneration based on the convergence of bioelectronics and biologics. The team has over 700 patent claims issued, pending, in process, optioned or licensed for organ regeneration and recovery. These include key issued and pending patents for bioelectric stimulation signaling sequences for stem cell homing via SDF1 and PDGF, muscle regeneration via Klotho and Follistatin, elasticity restoration via tropoelastin, nerve regeneration via IGF1 and sonic hedgehog. 9 issued patents and dozens of claims pending for bioelectric cancer treatment. Bioelectric controlled release of anti-aging protein Klotho for many applications.

Problem:

Organ deterioration will effect every single person on earth as they age. To date no other products are able to fully regenerate an aging, diseased or damaged organ.

Transplants are difficult to get and have rejection problems.

3D printed organs are difficult to integrate into the body.

Solution:

Leonhardt's Launchpads is on a quest to uncover the key elements to organ regeneration and has made significant progress.

The key to organ regeneration is both bioelectric signaling controls that tell the living cells via a program what to do combined with stem cells and biologics.

Technology:

Leonhardt's Launchpads is an innovation accelerator focused on organ regeneration with a combination of bioelectric signaling controlled regenerative protein expressions and when needed in the most severe cases repeat deliveries of stem cells in proprietary mixed composition of support factors.

Our proprietary bioelectric signals control stem cell homing, proliferation and differentiation. Also promote the growth of mature large diameter blood vessels when needed. We have bioelectric signaling sequences for muscle, nerve and elasticity regeneration.

Our proprietary organ regeneration composition is comprised of hypoxia pre-treated stem cells, exosomes, micro RNA gel, selected growth factors, secretome from amniotic sourcing, bioelectric pre-treated PRF, selected alkaloids and matrix.

Market Opportunity:

The market for a safe and effective organ regeneration technology would exceed \$1 trillion dollars annually.

Product Groups of Leonhardt's Launchpads + No. of Startups in Each:

- *Heart & Cardiovascular (9)
- *Brain (7)
- *Cosmetic, Personal Care & Reproductive Health (10)
- *Major Organ Regeneration (10)
- *Cancer (1)

Organs and conditions being served - heart, heart valve, aorta, blood pressure, blood clots, calcification, memory loss, stroke, traumatic brain injury, addiction, depression, stomach health, breast augmentation, skin, hair, erectile dysfunction, teeth, testosterone management, breathing, liver, kidney, lungs, pancreas, bladder and cancer.

Status:

18 products at clinical stage of development and 20 pre-clinical

Approaching 1000 patients in clinical studies. Running 83% success rate. No adverse events.

Over 700 patent claims issued, pending, optioned, licensed or in process



FORWARD LOOKING STATEMENT

This Executive Summary contains forward-looking statements related to future events or future performances. Forward-looking statements involve a variety of assumptions, estimates, risks and uncertainties that could result in actual events being materially different from those described in the forward-looking statements. Accordingly, investors should not rely on projections and other forward-looking statements in making an investment decision.